ReviewFrontiers in pediatrics2020
Biomarkers in COVID-19: An Up-To-Date Review.
Review in Frontiers in pediatrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 158 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
158 citing papers in PubMed, 2 syntheses or guidelines pooled it, 298 citations in OpenAlex.
- Systematic review with meta-analysis of mid-regional pro-adrenomedullin (MR-proadm) as a prognostic marker in Covid-19-hospitalized patients.Annals of medicine · 2023Pooled it
- Pooled it
- The effect of Nutrition Bio-shield superfood (NBS) on disease severity and laboratory biomarkers in patients with COVID-19: A randomized clinical trial.Microbial pathogenesis · 2022Trial
- Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials: Lessons from the CounterCOVID - imatinib study.CPT: pharmacometrics & systems pharmacology · 2021Trial
- The Ability of Serum Amyloid A to Discriminate Coronavirus Disease 2019 (COVID-19) Patients Who Stay Moderately Ill Versus Patients Who Become Severely Ill.Journal of clinical laboratory analysis · 2026Article
- Postpandemic Change in Demographic and Clinical Features of Patients With Omicron Who Were Hospitalized: Territory-Wide Retrospective Repeated Cross-Sectional Study in Hong Kong.JMIR public health and surveillance · 2026Article
- Differentiating Multisystem Inflammatory Syndrome in Children (MIS-C) from Acute COVID-19 Using Biomarkers: Toward a Practical Clinical Scoring Model.Biomedicines · 2026Article
- Hematological and biochemical markers for predicting severity in COVID-19 patients.BMC infectious diseases · 2026Observational
- Biochemical Markers as Predictors of Coronavirus Disease-2019 Severity and Intensive Care Unit Admission: A Retrospective Study in Saudi Arabia.Annals of African medicine · 2026Observational
- Toward Precision in Myocardial Injury Management: A Critical Synthesis and the C.A.L.I.B.R.A.T.E. Framework for Biomarker Integration.Clinical Medicine Insights. Cardiology · 2026Review
- Comparison of biomarkers and laboratory results in unaffected, moderate, and severe COVID-19 recovered patients.Future science OA · 2025Article
- miRNA biomarkers for prognosis and therapy monitoring in a multi-ethnic cohort with SARS-CoV-2 infection.Scientific reports · 2025Article
- Evaluation of Function and Biochemical Parameters of Platelet Concentrates (PCs) Prepared From Blood Donors With a History of COVID-19 During the Platelet Storage.Journal of clinical laboratory analysis · 2025Article
- Immune biomarkers as early indicators of renal damage in type 1 diabetic children: A step toward translational medicine.World journal of diabetes · 2025Article
- Omics for searching plasma biomarkers associated with unfavorable COVID-19 progression in hypertensive patients.Scientific reports · 2025Article
- Serum Lactate Dehydrogenase Levels Reflect the Lung Injury Extension in COVID-19 Patients at Hospital Admission.Immunity, inflammation and disease · 2025Article
- The predictive value of the LDH-albumin ratio on poor clinical course and mortality in COVID-19 patients: A single-center study.Medicine · 2025Observational
- Efficacy and Safety of Nebulized Sodium Bicarbonate in Adults with COVID-19 (SODIC): A Randomized, Single-Center, Double-Blinded, Controlled Trial.Current therapeutic research, clinical and experimental · 2025Article
- Cardiac Biomarkers Aid in Differentiation of Kawasaki Disease from Multisystem Inflammatory Syndrome in Children Associated with COVID-19.Pediatric cardiology · 2025Article
- Molecular analysis of long COVID and new-onset diabetes mellitus: pathobiological relationships and current mechanistic views.Frontiers in endocrinology · 2025Review
98 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ongoing pandemic of coronavirus disease 2019 (COVID-19) poses several challenges to clinicians. Timely diagnosis and hospitalization, risk stratification, effective utilization of intensive care services, selection of appropriate therapies, monitoring and timely discharge are essential to save the maximum number of lives. Clinical assessment is indispensable, but laboratory markers, or biomarkers, can provide additional, objective information which can significantly impact these components of patient care. COVID-19 is not a localized respiratory infection but a multisystem disease caused by a diffuse systemic process involving a complex interplay of the immunological, inflammatory and coagulative cascades. The understanding of what the virus does to the body and how the body reacts to it has uncovered a gamut of potential biomarkers. This review discusses the different classes of biomarkers - immunological, inflammatory, coagulation, hematological, cardiac, biochemical and miscellaneous - in terms of their pathophysiological basis followed by the current evidence. Differences between children and adults are highlighted. The role of biomarkers in the diagnosis and management of Multisystem Inflammatory Syndrome in Children (MIS-C) is reviewed. The correlation of biomarkers with clinical and radiological features and the viral load, temporal evolution and the effect of treatment remain to be studied in detail. Which biomarker needs to be evaluated when and in whom, and how best this information can contribute to patient care are questions which currently lack convincing answers. With the evidence currently available broad guidelines on the rational use of available biomarkers are presented. Integrating clinical and laboratory data, monitoring trends rather than a single value, correlating with the natural course of the disease and tailoring guidelines to the individual patient and healthcare setting are essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.